Pimozide has 51 known drug interactions based on U.S. FDA drug labeling data. Of these, 44 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aprepitant, Arsenic Trioxide, Azole Antifungals. Patients taking Pimozide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 51
- Contraindicated
- 44
- Major
- 2
- Moderate
- 5
Contraindicated (44)
- Pimozide + Aprepitant— Increased pimozide exposure. CINVANTI is contraindicated.
- Pimozide + Arsenic Trioxide— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Azole Antifungals— Pimozide should not be administered concomitantly with azole antifungal agents as inhibitors of CYP 3A4 metabolism.
- Pimozide + Chlorpromazine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Citalopram— Concomitant use increases plasma concentrations of pimozide and may increase risk of QT prolongation and ventricular arr…
- Pimozide + Citalopram Hydrobromide— Concomitant use increases plasma concentrations of pimozide and may increase risk of QT prolongation and ventricular arr…
- Pimozide + Dextromethorphan Hydrobromide And Quinidine Sulfate— Do not use with drugs that both prolong QT interval and are metabolized by CYP2D6.
- Pimozide + Dofetilide— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Dolasetron Mesylate— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Droperidol— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Escitalopram— Concomitant use increases plasma concentrations of pimozide and may increase risk of QT prolongation and ventricular arr…
- Pimozide + Escitalopram Oxalate— Concomitant use increases plasma concentrations of pimozide and may increase risk of QT prolongation and ventricular arr…
- Pimozide + Fluoxetine— Do not use fluoxetine with pimozide due to QT interval prolongation risk.
- Pimozide + Fluoxetine Hydrochloride— Do not use fluoxetine with pimozide due to QT prolongation risk.
- Pimozide + Fosaprepitant— Fosaprepitant is contraindicated with pimozide due to increased pimozide exposure via CYP3A4 inhibition.
- Pimozide + Fosaprepitant Dimeglumine— Fosaprepitant for injection is contraindicated due to increased pimozide exposure via CYP3A4 inhibition.
- Pimozide + Gatifloxacin— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Halofantrine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Itraconazole— Coadministration is contraindicated. Increased plasma concentrations may lead to QT prolongation and ventricular tachyar…
- Pimozide + Ketoconazole— Ketoconazole increases pimozide plasma concentrations, potentially causing QT prolongation and life-threatening ventricu…
- Pimozide + Levoketoconazole— Concomitant use is contraindicated due to increased risk of QT prolongation and torsades de pointes.
- Pimozide + Levomethadyl Acetate— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Macrolide Antibiotics— Use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhyth…
- Pimozide + Mefloquine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Mesoridazine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Mifepristone— Mifepristone increases pimozide exposure; concomitant use is contraindicated due to narrow therapeutic range.
- Pimozide + Moxifloxacin— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Olanzapine And Fuoxetine— Do not use olanzapine and fluoxetine capsules in combination with pimozide.
- Pimozide + Paroxetine— Increased plasma concentrations may increase risk of QTc prolongation and ventricular arrhythmias. Paroxetine is contrai…
- Pimozide + Paroxetine Hydrochloride— Increased plasma concentrations of pimozide may increase the risk of QTc prolongation and ventricular arrhythmias.
- Pimozide + Paroxetine Hydrochloride Hemihydrate— Paroxetine increases pimozide AUC by 151% and Cmax by 62%, leading to increased QT prolongation risk. Contraindicated du…
- Pimozide + Pentamidine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Posaconazole— Concomitant use may result in increased plasma concentrations leading to QTc prolongation and torsades de pointes.
- Pimozide + Probucol— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Protease Inhibitors— Pimozide should not be administered concomitantly with protease inhibitors as inhibitors of CYP 3A4 metabolism.
- Pimozide + Quinidine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Rolapitant— Increased plasma concentrations associated with serious and life-threatening QT prolongation and Torsades de Pointes.
- Pimozide + Sertraline— Increased plasma concentrations may increase risk of QTc prolongation and ventricular arrhythmias. Concomitant use is co…
- Pimozide + Sertraline Hydrochloride— Concomitant use increases pimozide plasma concentrations, increasing risk of QTc prolongation and ventricular arrhythmia…
- Pimozide + Sotalol— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Sparfloxacin— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Tacrolimus— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Thioridazine— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
- Pimozide + Ziprasidone— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
Major (2)
- Pimozide + Anagrelide— Avoid use; may prolong QT interval and increase risk of arrhythmias with anagrelide.
- Pimozide + Anagrelide Hydrochloride— Avoid concomitant use due to QT prolongation risk.
Moderate (5)
- Pimozide + Alcohol— Pimozide may potentiate CNS depressant effects of alcohol.
- Pimozide + Bromocriptine Mesylate— Pimozide is a dopamine antagonist that results in decreased efficacy of bromocriptine mesylate.
- Pimozide + Deferasirox— Deferasirox may induce CYP3A4 resulting in decreased pimozide concentration. Monitor for reduced effectiveness.
- Pimozide + Methenamine, Sodium Phosphate, Monobasic, Monohydrate, Phenyl Salicylate, Methylene Blue, And Hyoscyamine Sulfate— Methylene blue inhibits CYP3A4/5 and CYP1A2 metabolism. Pimozide has narrow therapeutic index; clinical relevance unknow…
- Pimozide + Palbociclib— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.